公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2021 | Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer | Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU ; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. | Clinical Cancer Research | 14 | 10 | |
2021 | A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer | Schmid P.; Sablin M.-P.; Bergh J.; Im S.-A.; YEN-SHEN LU ; Mart?nez N.; Neven P.; Lee K.S.; Morales S.; P?rez-Fidalgo J.A.; Adamson D.; Gon?alves A.; Prat A.; Jerusalem G.; Schlieker L.; Espadero R.-M.; Bogenrieder T.; Huang D.C.-L.; Crown J.; Cort?s J. | Breast Cancer Research | 17 | 15 | |
2004 | Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma | YEN-SHEN LU ; Hsu C; Li C.-C; SUNG-HSIN KUO ; Yeh K.-H; Yang C.-H; Hsu C.-H; Wu C.-Y; Cheng A.-L. | Hepato-Gastroenterology | 14 | 13 | |
2011 | Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer | YEN-SHEN LU ; Chen D.-R.; Tseng L.-M.; Yeh D.-C.; Chen S.-T.; Hsieh C.-M.; Wang H.-C.; Yeh H.-T.; SUNG-HSIN KUO ; CHIUN-SHENG HUANG | Cancer Chemotherapy and Pharmacology | 10 | 8 | |
2002 | A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil | CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; CHIH-HSIN YANG ; YEN-SHEN LU ; CHIA-CHI LIN ; Bu C.-F.; KUN-HUEI YEH | Anticancer Research | 12 | 12 | |
2005 | Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.-F.; CHIUN HSU ; SUNG-HSIN KUO ; Li Jr. S.; ANN-LII CHENG | Oncology | 22 | 22 | |
2005 | Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.F.; Chao H.J.; Ta-Chen Huang ; Chung C.Y.; Chang C.S.; CHIH-HSIN YANG ; ANN-LII CHENG | British Journal of Cancer | 7 | 7 | |
2002 | Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma | CHIUN HSU ; CHIUN-SHENG HUANG ; Chao T.-Y.; YEN-SHEN LU ; Bu C.-F.; Chen M.M.; KING-JEN CHANG ; ANN-LII CHENG | Cancer | 12 | 11 | |
2007 | A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer | CHIA-CHI LIN ; ANN-LII CHENG ; CHIH-HUNG HSU ; YEN-SHEN LU ; CHIUN HSU ; KUN-HUEI YEH ; Wu C.-Y.; CHIUN-SHENG HUANG ; CHIH-HSIN YANG | Anticancer Research | 2 | 2 | |
2017 | Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen | I-CHUN CHEN ; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; CHING-HUNG LIN ; Wei-Wu Chen T.; ANN-LII CHENG ; YEN-SHEN LU | Scientific Reports | 23 | 20 | |
2013 | Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas | Wu P.-F.; Huang W.-C.; CHIH-HSIN YANG ; YEN-SHEN LU ; JIN-YUAN SHIH ; SHANG-GIN WU ; CHING-HUNG LIN ; ANN-LII CHENG | Journal of Neuro-Oncology | 8 | 5 | |
2019 | PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study | MING-HAN YANG ; I-CHUN CHEN ; YEN-SHEN LU | Journal of the Formosan Medical Association | 21 | 17 | |
2015 | A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis | Wu P.-F.; CHING-HUNG LIN ; CHING-HUA KUO ; WEI-WU CHEN ; Yeh D.-C.; Liao H.-W.; Huang S.-M.; ANN-LII CHENG ; YEN-SHEN LU | BMC Cancer | 48 | 36 | |
2016 | A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer | BANG-BIN CHEN ; YEN-SHEN LU ; CHING-HUNG LIN ; WEI-WU CHEN ; Wu P.-F.; CHAO-YU HSU ; CHIH-WEI YU ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | BMC Cancer | 20 | 17 | |
2023 | Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer | WEI-WU CHEN ; Hsiao, Wen; Dai, Ming-Shen; CHING-HUNG LIN ; DWANG-YING CHANG ; I-CHUN CHEN ; MING-YANG WANG ; Chang, Shu-Han; Huang, Shu-Min; ANN-LII CHENG ; Wu, Ko-Wen; Tan, Kien Thiam; YEN-SHEN LU | Breast cancer research and treatment | 0 | 0 | |
2007 | Pneumatosis coli after etoposide chemotherapy for breast cancer | I-LUN SHIH ; YEN-SHEN LU ; HSIU-PO WANG ; KAO-LANG LIU | Journal of Clinical Oncology | 12 | 12 | |
2023 | Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials | André, F; Su, F; Solovieff, N; Hortobagyi, G; Chia, S; Neven, P; Bardia, A; Tripathy, D; YEN-SHEN LU ; Lteif, A; Taran, T; Babbar, N; Slamon, D; Arteaga, C L | Annals of oncology : official journal of the European Society for Medical Oncology | 3 | 0 | |
2010 | Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin | YU-YUN SHAO ; KUAN-TING KUO ; Hu F.-C.; YEN-SHEN LU ; CHIUN-SHENG HUANG ; JAU-YU LIAU ; Lee W.-C.; CHIUN HSU ; WEN-HUNG KUO ; KING-JEN CHANG ; CHING-HUNG LIN ; ANN-LII CHENG | Japanese Journal of Clinical Oncology | 28 | 24 | |
2010 | The prevalence and assessment of ErbB2-positive breast cancer in Asia: A literature survey | Tan Y.O; Han S; YEN-SHEN LU ; Yip C.-H; Sunpaweravong P; Jeong J; Caguioa P.B; Aggarwal S; Yeoh E.M; Moon H. | Cancer | 17 | 16 | |
2011 | Prognostic molecular markers in Women aged 35 years or younger with breast cancer: Is there a difference from the older patients? | CHING-HUNG LIN ; YEN-SHEN LU ; CHIUN-SHENG HUANG ; KUAN-TING KUO ; Wang C.-C.; You S.-L.; PO-HAN LIN ; DWANG-YING CHANG ; WEN-HUNG KUO ; KING-JEN CHANG ; ANN-LII CHENG | Journal of Clinical Pathology | 8 | 8 | |